One observes, with a degree of detached amusement, that ACT Capital Management has decided to deploy some $8 million into TG Therapeutics. A bold stroke, perhaps? Or merely a desperate attempt to inject a little excitement into an otherwise terribly dull portfolio? One assumes the former, naturally.
A Spot of Trouble, You See
According to the filings – frightfully tedious documents, those – ACT acquired 268,875 shares. A substantial chunk of change, to be sure, representing 6.5% of their reportable U.S. equity holdings as of December. One gathers they’ve been having a bit of a flutter. Rather like backing a slightly lame racehorse, wouldn’t you say?
The Portfolio, My Dear
- Their top holdings, for the record, include Krystal Biotech ($14.92 million), CVX ($11.96 million), XOM ($9.93 million), Abivax ($8.62 million), and now, TG Therapeutics ($8.02 million). A diversified spread, if lacking a certain… panache.
- Shares of TG Therapeutics, one notes with a slight raising of the eyebrow, have been performing rather poorly. Down 30% over the past year, while the S&P 500 merrily trots along. One does wonder what they’re thinking.
A Snapshot, If You Please
| Metric | Value |
|---|---|
| Price (as of Monday) | $28.58 |
| Market capitalization | $4.6 billion |
| Revenue (TTM) | $616.3 million |
| Net income (TTM) | $447.2 million |
The Business, Briefly
TG Therapeutics, for those unfamiliar, dabbles in therapies for B-cell malignancies and autoimmune diseases. Monoclonal antibodies and small molecules, you understand. All frightfully technical, of course. They generate revenue through sales and licensing agreements. A perfectly respectable, if somewhat uninspired, business model.
What Does it All Mean?
The company seems to be navigating a transition period. Their multiple sclerosis treatment, BRIUMVI, is showing promise, having generated roughly $606.9 million in sales last year. A doubling in revenue is nothing to sneeze at, even in these modern times. However, investor guidance has been…disappointing. A target of $875 to $900 million for 2026 is ambitious, to say the least.
If TG can surpass these projections, a turnaround is certainly possible. Perhaps ACT Capital Management is banking on just that. Within their broader portfolio, the position aligns with other healthcare and biotech names, suggesting a willingness to embrace risk in pursuit of substantial returns. A perfectly sensible strategy, if one isn’t overly sensitive to the possibility of losing a few million. One assumes these people are accustomed to it.
It’s all a bit of a gamble, really. But then, what isn’t? And frankly, a little bit of excitement is precisely what the market needs. Don’t you agree?
Read More
- Spotting the Loops in Autonomous Systems
- Seeing Through the Lies: A New Approach to Detecting Image Forgeries
- Staying Ahead of the Fakes: A New Approach to Detecting AI-Generated Images
- The Glitch in the Machine: Spotting AI-Generated Images Beyond the Obvious
- The Best Directors of 2025
- 20 Best TV Shows Featuring All-White Casts You Should See
- Julia Roberts, 58, Turns Heads With Sexy Plunging Dress at the Golden Globes
- Palantir and Tesla: A Tale of Two Stocks
- How to rank up with Tuvalkane – Soulframe
- Gold Rate Forecast
2026-03-16 23:04